403 related articles for article (PubMed ID: 27521306)
41. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
42. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
[TBL] [Abstract][Full Text] [Related]
43. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
44. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
45. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
Wassie E; Finke C; Gangat N; Lasho TL; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Br J Haematol; 2015 Apr; 169(1):71-6. PubMed ID: 25521305
[TBL] [Abstract][Full Text] [Related]
46. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Shanavas M; Gupta V
Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
[TBL] [Abstract][Full Text] [Related]
47. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
48. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
49. Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M; Ribera JM; García O; Cabezón M; Vélez P; Marcé S; Xicoy B; Fernández C; Buch J; Cortes M; Plensa E; Gallardo D; Boqué C; Feliu E; Zamora L
Eur J Haematol; 2016 Oct; 97(4):331-5. PubMed ID: 26714837
[TBL] [Abstract][Full Text] [Related]
50. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
51. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
52. Classification of myeloproliferative neoplasms and prognostic factors.
Passamonti F
Am Soc Clin Oncol Educ Book; 2012; ():419-24. PubMed ID: 24451774
[TBL] [Abstract][Full Text] [Related]
53. Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis.
Ding N; Zhang Z; Yang W; Ren L; Zhang Y; Zhang J; Li Z; Zhang P; Zhu X; Chen X; Fang X
Genomics Proteomics Bioinformatics; 2017 Feb; 15(1):37-48. PubMed ID: 28185911
[TBL] [Abstract][Full Text] [Related]
54. The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy.
Gallo D; Nicoli P; Calabrese C; Gaidano V; Petiti J; Rosso V; Signorino E; Carturan S; Bot-Sartor G; Volpe G; Frassoni F; Saglio G; Cilloni D
Cancer Med; 2016 Jul; 5(7):1650-3. PubMed ID: 27167495
[TBL] [Abstract][Full Text] [Related]
55. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.
Guglielmelli P; Rotunno G; Pacilli A; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pieri L; Fjerza R; Pietra D; Cilloni D; Sant'Antonio E; Salmoiraghi S; Passamonti F; Rambaldi A; Barosi G; Barbui T; Cazzola M; Vannucchi AM
Am J Hematol; 2016 Sep; 91(9):918-22. PubMed ID: 27264006
[TBL] [Abstract][Full Text] [Related]
56. One thousand patients with primary myelofibrosis: the mayo clinic experience.
Tefferi A; Lasho TL; Jimma T; Finke CM; Gangat N; Vaidya R; Begna KH; Al-Kali A; Ketterling RP; Hanson CA; Pardanani A
Mayo Clin Proc; 2012 Jan; 87(1):25-33. PubMed ID: 22212965
[TBL] [Abstract][Full Text] [Related]
57. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.
Lucijanic M; Mitrovic Z; Cicic D; Prka Z; Pejsa V; Livun A; Stoos-Veic T; Romic Z; Zivkovic M; Lucijanic I; Fabris Z; Kusec R
Int J Hematol; 2018 Feb; 107(2):166-172. PubMed ID: 29022201
[TBL] [Abstract][Full Text] [Related]
58. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.
Elena C; Passamonti F; Rumi E; Malcovati L; Arcaini L; Boveri E; Merli M; Pietra D; Pascutto C; Lazzarino M
Haematologica; 2011 Jan; 96(1):167-70. PubMed ID: 20884708
[TBL] [Abstract][Full Text] [Related]
59. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Horvat NP; Abdallah EF; Xie Z; Al Ali N; Yun S; Walker A; Padron E; Sallman D; Chan O; Lancet J; Komrokji R; Kuykendall AT
Ann Hematol; 2024 Jan; 103(1):117-123. PubMed ID: 38030891
[TBL] [Abstract][Full Text] [Related]
60. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
Mahmud M; Vasireddy S; Gowin K; Amaraneni A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
